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Introduction: Several new agents are being tested in clinical trials
for patients with non-small cell lung cancer (NSCLC). A survey of
ongoing clinical trials in NSCLC in the ClinicalTrials.gov website
would help identify areas that require further attention in the future.
Methods: We conducted a survey of ongoing clinical trials on NSCLC
registered in the ClinicalTrials.gov website. The advanced search op-
tion was applied using the terms “non small cell lung cancer,” “open
studies,” “interventional,” and “adults 18 years or older.”
Results: Of the 493 eligible trials, 77 (15.6%) were phase III, 92
(18.7%) were phase I, and 240 (48.7%) were phase II trials.
Universities were listed as the primary sponsor for 224 (45.4%)
trials and pharmaceutical industry for 166 (33.7%) trials. Majority of
the trials were multicenter studies (56.8%) and were being con-
ducted exclusively within the United States (51.3%). A large pro-
portion of phase II and III clinical trials (77.2%) were focused on
patients with advanced-stage disease. The most frequently used end
points were progression-free survival (27.1%) followed by tumor
response rate (22.9%) and overall survival (16.6%). Although bi-
omarker analysis was included in 185 (37.5%) trials, only 39 (7.9%)
trials used biomarkers for patient selection.
Conclusions: Progression-free survival is the end point most com-
monly used to assess the effectiveness of experimental regimens,
and biomarker-based patient selection is rarely used in ongoing
clinical trials for NSCLC.
(J Thorac Oncol. 2010;5: 1116–1119)
Lung cancer is the leading cause of cancer-related death inthe United States. In 2009, it was estimated that there
would be 219,440 new cases and 159,000 deaths from lung
cancer in the United States.1 The fact that lung cancer clinical
trials account for 14% of ongoing oncology trials worldwide
is a testament to the vigorous interest in pursuing novel
treatment options for this disease.2
Successful introduction of a new anticancer drug in the
United States requires regulatory approval by the Food and
Drug Administration. It takes more than 9 years to complete
the required preclinical studies and a series of clinical trials.3
Drug development is an expensive process,4 more specifi-
cally, the clinical trials are very expensive. Vast majority of
cancer clinical trials fail to reach their stated end points.3
With the availability of several new agents, numbers of
clinical trials have increased exponentially. For the first time in
the history of clinical research, we could now survey currently
ongoing clinical trials using a publicly available database to
obtain useful information not only on the current trends in cancer
research but also learn how to prioritize future research. More
importantly, a periodic review (annually or biannually) of the
process will be necessary to provide the necessary perspective
and framework for drug development in the future. The Clini-
calTrials.gov website is a registry for clinical trials and provides
valuable information on ongoing clinical trials. This registry was
established by the Department of Health and Human Services
through the National Institutes of Health with the primary purpose
of improving public access to clinical trials, and it currently contains
approximately 85,760 clinical trials. Furthermore, the International
Committee of Medical Journal Editors (ICMJE) requires that all
clinical trials be enrolled in a public registry before patient enroll-
ment if they are to be considered for publication. The ClinicalTri-
als.gov website states that it “provides a vehicle which allows
organizations and individuals to provide the data requested by
ICMJE” (http://prsinfo.clinicaltrials.gov/icmje.html). We conducted
a survey of ongoing clinical trials listed in the ClinicalTrials.gov
website for patients with non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
We used the advanced search option available on the
ClinicalTrials.gov website using the search term “non small
cell lung cancer.” In the drop down menus, we chose “open
studies” for recruitment status and “interventional” for study
type. We excluded age group “birth to 17 years of age” in
additional criteria. Our study included all trials reported until
June 2, 2009, in the website. We excluded trials that did not
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involve patients with NSCLC and clinical trials that did not
include any form of medical therapy.
We extracted the following information: (1) type of
clinical trial (phase I, II, or III), (2) recruiting status, (3)
tumor, node, metastasis stage, (4) study design: randomiza-
tion, control group, and number of study arms, (5) location,
(6) the number of trial centers, (7) primary sponsor, (8) target
enrollment, (9) treatment setting, (10) treatment modality,
(11) date of trial activation, (12) time elapsed since the study
was open for enrollment, and (13) primary outcome measure.
RESULTS
Our search identified 658 trials of which 165 were
excluded, because they involved patients with small cell lung
cancer or did not include any form of medical therapy in the
study arm. Of the 493 trials selected, 472 (95.7%) were
actively recruiting and 19 (3.9%) were not yet open for
enrollment. However, two (0.4%) trials were listed as closed
to enrollment despite choosing the option “open” in the drop
down menu for recruitment status in the advanced search
option. Based on an intention to treat principle, we included
these two trials in our analysis. Majority of the studies were
phase II trials (240, 48.7%) followed by phase I (92, 18.7%),
phase III (77, 15.6%), and phase I/II trials (61, 12.4%). Two
hundred twenty-four clinical trials (45.4%) were sponsored
by universities, 166 (33.7%) by pharmaceutical industry, and
43 (8.7%) by cooperative groups. Nearly half of the studies
were conducted exclusively within the United States (51.3%)
and in multiple locations (56.8%) (Table 1).
A significant proportion of the phase II trials (including
the phase II portion of phase I/II trials) were nonrandomized
(64.1%), open-label (88%), or had single-arm (60.8%). In phase
III trials, the experimental regimen was compared with standard
of care or active control in 64 (83.1%) trials and best supportive
care only in 13 (16.9%) trials (Table 2). In addition, 45 (58.4%)
phase III trials had an open-label design. The median number of
patients planned for enrollment was 65.5 (range, 3–600) in
phase II trials and 600 (range, 80–2270) in phase III trials.
Progression-free survival was the primary outcome in 27.1% of
all trials followed by tumor response rate in 22.9% and overall
survival in 16.6%. Other primary outcomes measured were
quality of life, disease-free survival, immunologic responses, or
traditional phase I end points. Response rate was the primary end
point in 36.9% of phase II trials, followed by progression-free
survival in 35.2% and overall survival in 10.6%. Other primary
outcomes measured in phase II trials were safety and toxicity,
immunologic response, quality of life, and disease-free survival.
Overall survival was the primary outcome measure in nearly
two-thirds of all phase III studies, whereas progression-free
survival was the primary end point in the remaining one-third.
A large proportion (77.2%) of the phase II and III
clinical trials were focused on patients with advanced-stage
disease, with 34.1% of the trials on first-line chemotherapy,
34.7% on second-line or more, and 2.9% on maintenance
therapy (Table 3). Only 10% of the clinical trials involved
concurrent chemotherapy and radiation. The proportion of
TABLE 1. Characteristics of All Open Clinical Trials in
ClinicalTrials.gov
Number of Trials (%)
Type of clinical trials
Phase I 92 (18.7)
Phase II 240 (48.7)
Phase I/II 61 (12.4)
Phase III 77 (15.6)
Phase II/III 3 (0.6)
Phase IV 8 (1.6)
Unspecified 12 (2.4)
Primary sponsor
Industry 166 (33.7)
Cooperative group 43 (8.7)
University 224 (45.4)
NCI 18 (3.7)
Others 42 (8.5)
Recruiting status of clinical trials
Actively recruiting 472 (95.7)
Not yet open for recruitment 19 (3.9)
Closed to recruitment but still open 2 (0.4)
Number of study locations
Single study location 213 (43.2)
Multiple study locations 280 (56.8)
Location of trial centers
In United States 253 (51.3)
Outside United States 177 (35.9)
Both 63 (12.8)
NCI, National Cancer Institute.
TABLE 2. Characteristics of Phase II and III Clinical Trials
Study Design
Number of
Phase II
Trials (%)a
Number of
Phase II/III
Trials (%)
Number of
Phase III
Trials (%)
Randomization
Randomized trials 108 (35.9) 3 (100) 77 (100)
Nonrandomized trials 193 (64.1)
Open label 265 (88.0) 2 (66.7) 45 (58.4)
Single blinded 1 (0.3) 1 (1.3)
Double blinded 25 (8.3) 1 (33.3) 24 (31.2)
Unknown 10 (3.3) 7 (9.1)
Number of treatment arms
Single arm 183 (60.8)
Two arms 97 (32.2) 3 (100) 69 (89.6)
Three or more arms 21 (7.0) 8 (10.4)
Type of control arm
Placebo 5 (1.7) 2 (66.7) 13 (16.9)
Standard care or active control 102 (33.9) 1 (33.3) 64 (83.1)
Uncontrolled 194 (64.4)
Primary outcome
Overall survival 32 (10.6) 50 (64.9)
Progression-free survival 106 (35.2) 3 (100) 21 (27.3)
Tumor response rate 111 (36.9) 1 (1.3)
Quality of life 3 (1.0) 1 (1.3)
Efficacy/feasibility 10 (3.3) 1 (1.3)
Others or unspecified 38 (12.7) 2 (2.6)
Disease-free survival 1 (0.33) 1 (1.3)
a Includes phase I/II studies and phase II studies.
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trials for patients with early-stage NSCLC receiving adjuvant
or neoadjuvant therapy was 12.3%.
Cytotoxic chemotherapy was the primary treatment
modality in 26.8% of all phase II and phase III clinical trials;
targeted agents in 29.1%; combined cytotoxic and targeted
therapy in 30.1%; and others including immunomodulators,
chemosensitizing agents, and alternate therapies in 14%.The
commonly studied targeted agents in these trials were epider-
mal growth factor receptor (EGFR) inhibitors and vascular
epidermal growth factor receptor tyrosine kinase inhibitors.
Other targeted agents included histone deacetylase inhibitors,
insulin growth factor inhibitors, proteasome inhibitors, and
proapoptotic agents (Table 4). EGFR inhibitors were more
likely to be evaluated as single agents (39.8%) than vascular
epidermal growth factor receptor inhibitors (18.5%).
Biomarker analysis was included as one of the study
objectives in 185 (37.5%) of the total 493 trials. Of the 185
trials, 34 (18.4%) were phase I trials, 20 (10.8%) were phase
I/II trials, 93 (50.3%) were phase II trials, and 27 (14.6%)
were phase III trials (Table 5). Of the trials that included
biomarker analysis, monotherapy with a targeted agent was
studied in 79 (42.7%) trials, combined chemotherapy and
targeted therapy in 46 (24.9%) trials, and chemotherapy alone
in 24 (13.0%) trials. More importantly, biomarker-based
patient selection was used in only 39 trials (7.9%). EGFR
expression or mutation status was the most common biomar-
ker in 17 (43.6%) trials used to select patients followed by
K-ras mutation status in five (12.8%) trials and markers for
DNA repair in five trials (12.8%).
Because the time line for patient enrollment is quite
different for phase II and phase III studies, we analyzed them
separately. A significant proportion of phase II trials with
universities listed as primary sponsor were open for more
than 2 years (52.5%) compared with trials sponsored by
co-operative group (23%) or industry (16.7%) (Table 6). A
similar trend was observed in phase III trials as well, with
50% of all university-sponsored trials open for more than 3
years compared with 23.0% of cooperative group and 18.2%
of industry-sponsored trials (Table 7).
DISCUSSION
Our survey of the ClinicalTrials.gov web site suggest
that more than half of all ongoing clinical trials in NSCLC are
phase II trials. Majority of the clinical trials for NSCLC are
conducted in multiple centers across the United States and
TABLE 3. Treatment Setting in Phase II and III Clinical Trials
Treatment Settinga Number of Trials (%)
Chemoprevention trials 2 (0.5)
Adjuvant therapy 22 (5.8)
Neoadjuvant therapy 18 (4.7)
Adjuvant/neoadjuvant therapy 7 (1.8)
Concurrent chemoradiotherapy 38 (10.0)
Advanced-stage disease
First line 130 (34.1)
First or second line 7 (1.8)
Second line or more 132 (34.7)
Maintenance 11 (2.9)
Unspecified 14 (3.7)
a Includes phase I/II, II, II/III, and III trials.
TABLE 4. Clinical Trials on Targeted Agents in the
Treatment of NSCLC
Targeted Agentsa
Single
Agent
Combination
With
Targeted
Agents
With
Chemotherapy
With
Other
Agents
EGFR inhibitors 47 (39.8) 31 (26.3) 34 (28.8) 5 (5.1)
VEGF inhibitors 17 (18.5) 12 (13.0) 62 (67.4) 1 (1.1)
mTOR inhibitors 2 (33.3) 1 (16.7) 3 (50.0) —
Histone deacetylase inhibitors 1 (12.5) 4 (50.0) 3 (37.5) —
IGF receptor antagonists — 5 (45.4) 6 (54.6) —
HER2 receptor antagonists 5 (71.4) 1 (14.3) 1 (14.3) —
Proapoptotic agents — 1 (33.3) 2 (66.7) —
Proteasome inhibitors 2 (33.3) 1 (16.7) 3 (50.0) —
Others 11 (31.4) 8 (22.9) 15 (42.8) 1 (2.9)
a Includes phase I/II, II, II/III, and III trials.
EGFR, epidermal growth factor receptor; VEGFR, vascular epidermal growth
factor receptor; mTOR, mammalian target of rapamycin; IGF, insulin growth factor;
NSCLC, non-small cell lung cancer.
TABLE 5. Clinical Trials with Biomarker Analysis
Characteristics n (%)
Biomarker(s) specified 185
Yes 145 (78.4)
No 40 (21.6)
Phase of the trial
Phase I 34 (18.4)
Phase I/II 20 (10.8)
Phase II 93 (50.3)
Phase II/III 1 (0.5)
Phase III 27 (14.6)
Phase IV 1 (0.5)
Not specified 9 (4.9)
Treatment regimen
Targeted therapy 79 (42.7)
Combined chemotherapy with targeted agents 46 (24.9)
Chemotherapy trials only 24 (13.0)
Immune 23 (12.4)
Alternative 2 (1.1)
Others 11 (5.9)
TABLE 6. Time Line for Patient Enrollment in Phase II Trials
0–12 mo >12–24 mo >24 mo
All phase II trials 93 (38.8) 56 (23.3) 91 (37.9)
Industry sponsor 41 (62.1) 14 (21.2) 11 (16.7)
Cooperative group 10 (38.5) 10 (38.5) 6 (23)
University sponsor 31 (25.4) 27 (22.1) 64 (52.5)
Other sponsors 7 (33.3) 5 (23.8) 9 (42.9)
NCI sponsor 4 (80) - 1 (20)
NCI, National Cancer Institute.
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sponsored by the universities. It is worth noting that not all
clinical trials conducted outside the United States are listed in
the ClinicalTrials.gov website. In fact, there are several
international registries that meet the ICMJE criteria for public
clinical trial registries. The World Health Organization website
provides a list of these international clinical trial registries
(http://www.who.int/ictrp/network/primary/en/index.html).
Both phase II and phase III clinical trials sponsored by univer-
sities were open for a longer period of time than trials sponsored
by industry or co-operative group.
A number of high-profile phase III studies in NSCLC
published recently have failed to reach their primary end points.
Novel phase II designs have been developed to enhance the
likelihood of success for the experimental regimen in the phase
III setting.5–14 Even though it has been shown to be a suboptimal
end point, response rate continues to be used as a primary end
point in majority of phase II trials.5,7,12 Quite disappointingly,
the majority of phase II studies we analyzed for this report were
staid and formulaic. In general, these single-arm phase II studies
were not designed to develop biomarkers that could then be
tested further in large clinical studies. In the absence of serious
and thoughtful effort to develop biomarkers in phase I or phase
II trials, it is not surprising that most of the phase III studies in
NSCLC conducted with molecularly targeted agents today are
not biomarker driven.
It is unlikely that the current approach of using molecu-
larly targeted agents with a narrow spectrum of activity would
benefit an unselected population of patients with a disease as
diverse as NSCLC. Clearly, a thorough understanding of the
drug, the target pathway(s), and potential factors that could
modulate pathways of interest is essential before launching
large-scale clinical trials. Insights gained from the clinical stud-
ies should truly promote a dynamic and constant two-way
interaction between the bench and clinic. Tissue collection
should be mandatory even in advanced disease settings, and a
systematic attempt should be made to identify predictive bi-
omarkers in phase II studies.
It is disappointing to note that the number of clinical
trials for early-stage and locally advanced NSCLC is dispro-
portionately low compared to advanced stage disease. Most
patients with advanced-stage disease do not have adequate
tumor tissue available for biomarker development and when
available, archived tumor tissue samples stored at the time of
diagnosis may not be relevant in patients with relapsed/
refractory disease.
A significant proportion of patients with early-stage
NSCLC relapse despite undergoing curative surgery or even
postoperative systemic therapy.15–17 Diligent use of molecularly
targeted agents in a well-defined cohort of patients selected
based on the biomarker status could dramatically improve the
cure rates in early-stage NSCLC. Moreover, the preoperative
setting may provide a window of opportunity to evaluate novel
targeted agents and develop predictive biomarkers. The current
tendency to develop phase III studies based on questionable or
marginally “positive” data should be discouraged. It is not just
the cumulative burden of repeated failures driving up the cost of
drug development process that eventually ricochets through a
creaky health system with high drug prices, but the disturbing
possibility that an agent quite effective in a small molecularly
defined population may never be developed after a negative
study in a broad undefined population. The current model may
have served us well in the bygone era dominated only by
cytotoxic chemotherapies. Clinical trial processes for cancer
therapy in general and NSCLC in particular should be adapted
and retailored to evaluate these novel agents, celebrated for their
narrow spectrum of targets, systematically and thoughtfully. As
with many things in life, a constant re-evaluation of the current
status and remodeling of our approach is necessary if we want to
make significant progress.
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